Runming Wang

Dr. Wang Runming is mainly engaged in cross-disciplinary research in the fields of Metals in Chemical Biology, Synthetic Biology, Synthetic Chemistry and Computational Biology. Through the development of innovative drugs and related chemical/biological tools, the structure and function of key metal proteins (enzymes) in pathogenic bacteria, viruses and eukaryotic cells are regulated, and a certain research foundation has been made in overcoming major scientific problems such as emerging infectious diseases (antimicrobial-resistant bacterial infections and COVID-19), malignant tumors and aging. He has presided over a number of funds, including the National Key R&D Program Project, National Science Fund for Excellent Young Scholars (Overseas), Young Scientists Fund of the National Natural Science Foundation of China, the Guangdong Natural Science Foundation General Project, and Special Fund Project of Shenzhen Medical Academy of Research and Translation. In the past five years, he has published papers in international academic journals such as Nat Microbiol, Nat Commun, Proc Natl Acad Sci USA, Chem Sci, iScience, etc. as the first author (including equivalent contributions) or corresponding author, with a total citation of >2200, h-factor 23, i10-factor 27 (based on Google Scholar data). Related research has applied for authorization/publication of 5 USPTO/PCT patents and 1 authorized Chinese patent. The relevant research work has been invited to hold media conferences many times and has been widely reported by dozens of Chinese and foreign media (Xinhuanet, CGTV, Reuters, Reference News, Phoenix.com, South China Morning Post, Science Daily, etc.).

The research group is recruiting postdoctoral fellows, research assistants, doctoral students, and master's students. Students with a background in chemistry, biology, chemical engineering, food science and engineering, computer science or related majors are welcome to join. Applicants are requested to send their application materials (personal profile, research results, future work plans, etc.) to runmingwang@sz.tsinghua.edu.cn.

Jan. 2014 - Feb. 2018, Ph.D. in Bioinorganic Chemistry, The University of Hong Kong, Hong Kong, P.R. China

Sep. 2012 - Dec. 2013, Analytical Chemistry, Wuhan Institute of Technology （Supervisor：Prof. Rong Chen）

Sep. 2008 - Jul. 2012, B. Eng. In Food Science and Engineering, Wuhan Institute of Technology  (Supervisor：Prof. Hongzhe Sun, Dr. Richard Yi-Tsun Kao)

Feb. 2022 - present, Assistant Professor, Tsinghua Shenzhen International Graduate School, China

Oct. 2018 - Oct. 2021, Postdoctoral Research Fellow, The University of Hong Kong

Mar. 2018 - Sep. 2021, Research Assistant, The University of Hong Kong

Member of Society of Biological Inorganic Chemistry, member of the Expert Committee of the China Pharmaceutical Industry Association, member of the China Biochemical Industry Youth Committee, member of the expert pool of the Shenzhen National High-tech Industry Innovation Center, member of the editorial board of Infectious Diseases Reviews, guest editor of Frontiers in Environmental Chemistry, Frontiers in Chemistry Guest Editor

Cell Culture Engineering (SIGS), Evidence-Based Medicine and Real-World Research (SIGS), Experiment Course of Modern Life Science and Biotechnology (SIGS)

Wang Runming has long been engaged in research in the interdisciplinary fields of bioinorganic chemistry, biology and microbiology. The research focus of Wang Runming's research group is mainly on metallo-related chemical biology, systems biology, and synthetic biology. In the early stage, through the research and development of innovative drugs and related (nano) chemical/biological tools, the structure and function of key metalloproteins (enzymes) in pathogenic bacteria, viruses, and eukaryotic cells were regulated, and the new infectious diseases (antimicrobial resistance) were overcome. Some achievements have been made in the research of major scientific issues such as drug infection and COVID-19), malignant tumors and aging. Wang Runming presided over or participated in a number of domestic and international fund projects. Has published more than 20 SCI papers in related fields, 2 highly cited papers, with a total number of citations > 1800. In the past five years, as the first author (including equal contribution) and corresponding author in Nat. Microb., Nat. Comm. (2 papers), Proc. Natl. Acad. Sci. U.S.A, Chem. Sci., iScience, Chem. Eng . J. and other international journals published papers. Authorized/published 4 USPTO/PCT patents and 1 Chinese patent. Relevant research work has been invited to hold media conferences for many times and has been widely reported by dozens of Chinese and foreign media (Xinhuanet, CGTV, Reuters, Reference News, Phoenix.com, South China Morning Post, Science Daily, etc.); new crown drug-related research was selected into the 2020 Annual Top 10 Innovation and Technology News in Hong Kong. Invited to participate in many domestic and foreign academic conferences and give oral reports.

We solemnly invite all aspiring master students, doctoral students and postdoctoral fellows to join Dr. Wang Runming's research team!

[1] National Key R&D Program Project, 2023-12 至 2028-12, in research, Co-PI

[2] National Science Fund for Excellent Young Scholars (Overseas), 2023-09 至 2026-08, in research, PI； 

[3] Young Scientists Fund of the National Natural Science Foundation of China, 2024/01-2026/12，in research, PI；

[4] Guangdong Natural Science Foundation of China (General Program), 2023-01 至 2025-12, in research, PI； 

[5] Special Fund Project of Shenzhen Medical Academy of Research and Translation，2024-01至2026-12，in research, PI；

[6] Tsinghua University Shenzhen International Graduate School Development Research Fund, 2022-07 至 2025-06, in research, PI；

[7] Tsinghua University Shenzhen International Graduate School Interdisciplinary Research Fund, 2023-07 至 2026-06，in research, PI； 

[8] Tsinghua University Shenzhen International Graduate School Interdisciplinary Research Fund, 2023-01 至 2025-12，in research, PI；

[9] University Research Committee of The University of Hong Kong, Seed Fund for Basic Research, 2021-04 至 2023-03, finished, Co-PI

[10] The Hong Kong Research Grants Council, PROCORE-France/Hong Kong Joint Research Scheme, F-HKU704/19, 2020-02 至 2022-01, finished, Co-PI

# Co-first author, * Correspondence author

1. Qi Z^#, Wang R^#, Wang M, Liu C, Koohi-Moghadam M, Wang H, Ho P-L, Li H, Sun H*,“Re-sensitization of mcr carrying multidrug resistant bacteria to 3 colistin by silver, Proc. Natl. Acad. Sci. U.S.A., 2022, 119, e2119417119.

2. Wang R^#, Chan J. F-W^#, Wang S^#, Li H, Zhao J, Ip K-Y, Zuo Z, Yuen K-K, Yuan S*, Sun H*, Orally administrated bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. Chem. Sci., 2022, 13, 2238-2248  [Back cover]

3. Yuan S^#, Wang R^#, Chan FW^#, Zhang J, Cheng T, Chik KH, Ye Z-W, Wang S, Jin L, Li H, Jin DY, Yuen KY*, Sun H*, Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters, Nat. Microbiol, 2020, 5, 1439–1448. [Local Top Ten innovation and technology news in 2020]]

4. Sun H^{# *}, Zhang Q^#, Wang R^{# *}, Wang H, Wong YT, Wang M, Hao Q, Yan A, Kao YT, Ho PL, Li H, Resensitizing superbugs carrying both blaMBL and mcr genes to antibiotics by auranofin, Nat. Commum., 2020, 11, 5263.

5. Wang R, Wang S, Chan S, Wang Y, Zhang Y, Zuo Z, Chan CF, Li H, Sun H*, Bismuth porphyrin antagonizes cisplatin-induced nephrotoxicity via unexpected metallothionein-independent mechanisms, iScience, 2020, 23, 101054.

6. Wang R^#, Lai TP^#, Gao P^#, Zhang H^#, Ho PL, Woo PC, Ma G, Kao RYT, Li H, Sun H*. Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors, Nat. Commum., 2018, 9, 439.[Highly cited paper]

7. WangR^#, Cheng G^#, Dai Z, Ding J, Liu Y, Chen R^*, Ionic liquid-employed synthesis of Bi₂E₃ (E=S, Se, and Te) hierarchitectures: the case of Bi₂S₃ with superior visible-light-driven Cr(VI) photoreduction capacity, Chem. Engineer. J., 2017, 327, 371-386.

8. Chan S^#, Wang R^#, Man K, Nicholls J, Li H, Sun H^*, Chan GC^*.Transl Oncol. 2016, 12, 788-799

9. Yuan S, Yin X, Meng X, Chan F-W, Ye Z-W, Riva L, Pache L, Chan C-Y, Lai P-M, Chan C-S, Poon K-M, Lee C-Y, Matsunaga N, Pu Y, Yuen C-K, Cao J, Liang R, Tang K, Sheng L, Du Y, Xu W, Lau C-Y, Sit KY, Au W-K, Wang R, Zhang Y-Y, Tang Y, Clausen T, Pihl J, Oh J, Sze K-H, Zhang J, Chu H, Kok K-H, Wang D, Cai X-H, D. Esko J, Hung F-N, Li R, Chen H, Sun H, Jin D-Y, Sun R, K. Chanda S, Yuen K-Y. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2, Nature, 2021, 593, 418–423.

10. Li H, Wang R, Sun H. Systems approaches for unveiling the mechanism of action of bismuth drugs: new medicinal applications beyond helicobacter pylori infection accounts of chemical research, Acc. Chem. Res. 2019 52, 216-227

Other relevant publications can be accessed via the following ways：

Google scholar link: https://scholar.google.com/citations?user=DWNINfAAAAAJ&hl=en&oi=ao

ORCID link: https://orcid.org/0000-0001-8525-5659

Research gate link：https://www.researchgate.net/profile/Runming-Wang

1. Wang R,  Li H,  Ip K-Y, Sun H. Chapter Six - Bismuth drugs as antimicrobial agents, Academic Press; 1st edition, 2020

2. Wang R, Li H, Sun H. Bismuth: Environmental Pollution and Health Effects, Elsevier, 2019

(1) Hongzhe Sun; Richard Yi Tsun Kao; Runming Wang; Tsz Pui Lai; Hongmin Zhang; Hongyan Li ; Bismuth (III) compounds and methods thereof, 2019-2-12, USPTO, US10201518B2，Granted.

(2) Hongzhe Sun; Chi-Fung Godfrey Chan; Shing Chan; Runming Wang ; Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy, 2023-01-17, USPTO, US11554138B2，Granted.

(3) Hongzhe Sun; Pak-Leung Ho; Runming Wang; Hongyan Li; Qi Zhang ; Silver-/gold-compounds and methods thereof, 2019-8-23, WIPO, PCT/CN2020/110444，filed.

(4) Hongzhe Sun; Kwok-Yung Yuen; Shuofeng Yuan; Runming Wang; Hongyan Li; Fuk-Woo Chan; Tianfan Cheng; Suyu Wang ; Compositions and methods for treating a SARS-CoV-2 infection, 2021-5-31, USPTO, 63/032,888，filed.

(5) 孙红哲; 高一村; 王润铭; 黎梓培;张宏民; 李洪艳,中国, ZL201780059904.3，Granted.

1.Gold Metal at International Exhibition of Inventions of Geneva (Team), 2023

2.Royal Society of Chemistry's Dalton Horizon Prize (Team), 2023

3.MIT Technology Review Innovators Under 35 Asia Pacific, 2022

4.National Overseas High-Level Talents (Youth) Project, 2022

5.Pengcheng Peacock Plan Specially Recruited Positions Category B Talents, 2022

6.Top Ten innovation and technology news of Hong Kong (Team), 2021

7. Faculty Knowledge Exchange (KE) Award (Team)，2021

8. 1st HKU-Pasteur Research Pole Fellowship (declined), 2021

9. Best Oral Presentation Award at 9th ASBIC9, 2018

10. Royal Society of Chemistry Books Awards at ASBIC8, 2016